You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-EPR1 (EPR1) Antibodies

Full name:
anti-Early-Phytochrome-Responsive1 Antibodies (EPR1)
On are 23 Early-Phytochrome-Responsive1 (EPR1) Antibodies from 5 different suppliers available. A total of 24 EPR1 products are currently listed.
list all antibodies Gene Name GeneID UniProt
EPR1 332 O15392

Show all species

Show all synonyms

Most Popular Reactivities for anti-EPR1 (EPR1) Antibodies

Select your species and application

anti-Human EPR1 Antibodies:

All available anti-EPR1 Antibodies

Go to our pre-filtered search.

More Antibodies against EPR1 Interaction Partners

Human Early-Phytochrome-Responsive1 (EPR1) interaction partners

  1. Survivin (show BIRC5 Antibodies) is a key gene for regulating squamous cell carcinoma (SCC (show CYP11A1 Antibodies)) cancer stem cell formation and cancer SCC (show CYP11A1 Antibodies) development.

  2. results indicate that survivin (show BIRC5 Antibodies) functions as a common mediator of gemcitabine- and TRAIL-induced cell death.

  3. We defined Survivin (show BIRC5 Antibodies) as a constitutive actor of HR in breast cancers, and implies that its inhibition would enhance cell vulnerability upon PARP (show COL11A2 Antibodies) inhibition.

  4. Studies on survivin (show BIRC5 Antibodies) in NP cells may aid in increasing the understanding of the complex processes underlying NP cell degeneration, and could provide fundamental information for gene therapy to inhibit this degeneration in vitro

  5. Suggest that the p53 (show TP53 Antibodies)-p21 (show CDKN1A Antibodies)-DREAM-CDE/CHR pathway regulates p53 (show TP53 Antibodies)-dependent repression of Survivin (show BIRC5 Antibodies), CDC25C (show CDC25C Antibodies), and PLK1 (show PLK1 Antibodies) in HCT116 cells.

  6. Overexpression of FOXM1 (show FOXM1 Antibodies), XIAP (show XIAP Antibodies), and Survivin (show BIRC5 Antibodies) contributes to the development of drug-resistance and is associated with poor clinical outcome in breast cancer patients.

  7. Survivin (show BIRC5 Antibodies), Bcl-2 (show BCL2 Antibodies), and KAI1 (show CD82 Antibodies) are metastasis-related factors in cervical cancer. Overexpression of survivin (show BIRC5 Antibodies) and Bcl-2 (show BCL2 Antibodies), and low expression of KAI1 (show CD82 Antibodies) promotes cervical cancer progress and metastasis.

  8. Survivin (show BIRC5 Antibodies), p53 (show TP53 Antibodies), and beta-catenin (show CTNNB1 Antibodies) overexpression, as prognostic markers, might suggest that the Urothelial carcinomas are biologically aggressive with the poor prognosis

  9. selective activity of 2DG treatment on Survivin (show BIRC5 Antibodies)-overexpressing tumor cells was also confirmed in a xenograft mouse model, which further supports our hypothesis that glycolysis inhibitors might be useful drugs in the treatment of NB

  10. findings suggest that USP22 (show USP22 Antibodies) may be involved in hepatocellular carcinoma progression in cooperation with survivin (show BIRC5 Antibodies).

EPR1 Antigen Profile

Antigen Summary

This gene is a member of the inhibitor of apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. IAP family members usually contain multiple baculovirus IAP repeat (BIR) domains, but this gene encodes proteins with only a single BIR domain. The encoded proteins also lack a C-terminus RING finger domain. Gene expression is high during fetal development and in most tumors, yet low in adult tissues. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.

Alternative names and synonyms associated with EPR1

  • baculoviral IAP repeat containing 5 (BIRC5) antibody
  • API4 antibody
  • EPR-1 antibody

Protein level used designations for EPR1

apoptosis inhibitor 4 , apoptosis inhibitor survivin , baculoviral IAP repeat-containing protein 5 , survivin variant 3 alpha

332 Homo sapiens
Selected quality suppliers for anti-EPR1 (EPR1) Antibodies
Did you look for something else?